Nutraplus India Plunges Deeper into Financial Distress; Auditor Doubts Going Concern

Nutraplus India Limited reported a net loss of ₹5.01 lakh for the financial year ended March 31, 2025. This marks a slight improvement from the ₹6.16 lakh net loss recorded in the previous fiscal year FY24.

Reader Takeaway: Loss narrowed slightly on cost control; but going concern, loan default, and governance risks loom high.

What just happened (today’s filing)

Nutraplus India Limited has disclosed its financial results for the fiscal year 2024-25, revealing a persistent net loss of ₹5,00,961.

This figure, while marginally better than the ₹6,15,824 loss in FY24, underscores the company's ongoing financial struggles.

The company's financial statements are marred by a severely eroded net worth, negative working capital, and negative cash flow.

Why this matters

The auditors' qualified opinion highlights substantial doubt about Nutraplus India's ability to continue as a going concern.

This situation stems from a confluence of factors including a significant loan default, inadequate internal controls, and critical governance lapses.

The backstory (grounded)

Nutraplus India Limited, which manufactures active pharmaceutical ingredients (APIs) and pharmaceuticals, has faced a challenging history. The company's assets were lost after it was declared a Non-Performing Asset (NPA) by Saraswat Bank, following a loan default of ₹76.24 crore. [cite: filing, 3]

Regulatory bodies like SEBI have previously taken action against entities involved in manipulating Nutraplus India's stock price, imposing fines for fraudulent trading practices.

What changes now

Shareholders face continued uncertainty due to the severe financial and operational challenges.

The company's ability to meet its liabilities is in question, impacting its operational continuity.

Significant governance and compliance failures persist, including an improperly constituted board and lack of required appointments.

Risks to watch

Going Concern Uncertainty: Auditors have expressed substantial doubt about the company's survival due to its dire financial state, including eroded net worth and negative cash flows. [cite: filing]

Loan Default and Asset Loss: The ₹76.24 crore default to Saraswat Bank led to the loss of all company assets, severely impacting operations. [cite: filing, 3]

Governance Deficiencies: The Board is not duly constituted, key statutory officers are missing, and meeting procedures are inadequate. [cite: filing]

Regulatory Non-Compliance: The company has failed to comply with multiple SEBI regulations, leading to trading suspensions and unpaid listing fees. [cite: filing]

Inadequate Internal Controls: The effectiveness of internal financial controls is compromised, raising operational risks. [cite: filing]

Peer comparison

Nutraplus India operates in the pharmaceuticals and API sector. Key peers include Aarti Drugs Ltd. and Divi's Laboratories Ltd., which are significantly larger and financially healthier companies. Aarti Drugs, for instance, had a market capitalization of ₹3,392.51 crore as of December 2021. These peers are not currently facing the existential challenges of going concern uncertainty and asset loss that plague Nutraplus India.

Context metrics (time-bound)

• Accumulated losses stood at ₹62.57 crore as of March 31, 2025.
• The company defaulted on a ₹76.24 crore loan from Saraswat Bank up to February 18, 2020.
• Net worth has been entirely eroded, and the company operates with negative working capital.

What to track next

Investors will monitor ongoing negotiations with banks for new loan and overdraft facilities.

The company's ability to secure external investments to fund operations is a critical factor for survival.

Any further regulatory actions or disclosures from SEBI or the stock exchanges will be closely watched.

Compliance with upcoming AGMs and book closure dates remains crucial, though challenging given the current state.